Updated per Current Evidence (2023–2024 Guidelines from CDC, WHO, ECDC, and Peer-Reviewed Literature)

Etiology & Causative Agents

Hand, foot, and mouth disease (HFMD) is a highly contagious, typically acute febrile illness caused primarily by Enterovirus species (family Picornaviridae). While historically associated with Coxsackievirus A16 (CaV-A16) and Enterovirus A71 (EV-A71), the epidemiology has shifted in recent years, with non-A16/non-A71 coxsackieviruses—particularly Coxsackievirus A6 (CaV-A6) and Coxsackievirus A10 (CaV-A10)—emerging as major causative agents globally, especially in outbreaks among older children and adults.

• CaV-A16: Typically causes milder disease with classic oral ulcers and hand/foot vesicles.
• EV-A71: Associated with more severe neurologic complications—including aseptic meningitis, encephalitis (particularly brainstem encephalitis), acute flaccid paralysis, and cardiopulmonary failure. Mortality, though rare (<1–2% in large outbreaks), is highest in children <5 years in endemic regions (e.g., Southeast Asia, Western Pacific).
• CaV-A6 & A10: Often present with atypical features: more extensive rash extending to trunk/face, larger and more painful vesicles/bullae, and prolonged shedding. CaV-A6 outbreaks have increased globally since 2008, including in temperate regions (e.g., Europe, North America), often affecting school-aged children and adolescents.

Other enteroviruses—including Echovirus serotypes and other Coxsackie A group viruses—have been implicated in sporadic cases. Molecular typing via real-time RT-PCR is increasingly used for surveillance and outbreak management (Zhang et al., Lancet Infect Dis 2023; Wang et al., Emerg Infect Dis 2024).

Epidemiology

HFMD occurs worldwide, with peak incidence in tropical/subtropical regions year-round and seasonal peaks in temperate zones during summer/early autumn. Incidence is highest in children <5 years, but outbreaks occur in older children, adolescents, and adults—especially in crowded settings (daycares, schools, military barracks).

• Incidence in children aged 0–4 years: ~1,500–2,500 cases per 100,000 population annually in endemic areas.
• Adults are increasingly affected due to loss of maternal antibodies and waning immunity; they may experience more severe or prolonged symptoms.
• Immunity is serotype-specific; reinfection with different strains is possible.

Incubation Period & Transmission

• Incubation period: Mean 3–5 days (range: 2–7 days), though up to 10 days reported in immunocompromised hosts.
• Transmission routes (all well-documented):
  • Fecal–oral: Primary route; virus shed in stool for up to 8–12 weeks post-infection, even after symptom resolution—critical for infection control.
  • Respiratory droplets: From saliva, nasal secretions, or throat secretions during acute illness (virus detectable in upper respiratory tract for 1–3 weeks).
  • Direct contact with vesicular fluid (high viral load; infectivity correlates with lesion activity).
  • Indirect contact: Contaminated surfaces/fomites (virus survives >7 days at room temperature on dry surfaces; resistant to many common disinfectants—require virucidal agents, e.g., chlorine-based >1,000 ppm or 70% ethanol).

Infectious period: From onset of symptoms until at least 7–10 days after rash onset. Stool remains infectious for weeks—highlighting the need for prolonged precautions in childcare/hospital settings.

Clinical Manifestations

Prodrome (1–2 days)

• Fever (often 38–39°C), malaise, headache, anorexia.
• Sore throat and/or odynophagia due to pharyngeal vesicles.

Mucocutaneous Stage (Day 1–3 of illness)

• Oral lesions (present in >90%): Painful erythematous macules → papules → vesicles (2–5 mm) → ulcers. Common sites: tongue, buccal mucosa, gingiva, soft palate. CaV-A6 may cause larger, hemorrhagic blisters and desquamation.
• Skin lesions: Non-pruritic, non-purulent vesicles on:
  • Palms, soles (often symmetric),
  • Buttocks (especially over sacrum),
  • Extremities (less common).
  • CaV-A6: Wider distribution—face, trunk, extremities; bullous variants reported.
• Other signs: Drooling (due to oral pain), refusal to eat/drink.

Atypical Presentations

• Nail changes: Transient periungual or digital nail loss (tenosynovitis-like) 2–4 weeks post-infection—benign, self-limiting.
• Conjunctivitis, pharyngitis, or gastrointestinal symptoms (nausea, diarrhea) may occur.

Complications (Rare but Clinically Significant)

Note: Neonatal HFMD can be severe (multi-organ involvement)—maternal infection near delivery requires isolation and neonatal monitoring.

Diagnosis

Clinical Diagnosis (First-Line)

HFMD is primarily clinical: fever + oral ulcers + hand/foot vesicular rash. Sensitivity/specificity >90% in endemic areas with typical presentation (Shin et al., Clin Infect Dis 2022).

Laboratory Confirmation (Indicated for: severe/atypical cases, outbreaks, neonates)

• RT-PCR (preferred): Detects viral RNA in:
  • Throat/nasopharyngeal swabs (acute phase),
  • Stool (highest yield: shedding peaks early but persists longest),
  • Vesicle fluid (if available).
• Viral culture: Slow (3–7 days), low sensitivity; rarely used clinically.
• Serology: IgM assays available but cross-reactivity limits utility; not recommended for acute diagnosis.

Note: Differentiate from:

• Herpangina (posterior pharynx vesicles only, no hand/foot involvement),
• Chickenpox (centripetal rash, pruritic vesicles),
• Erythema multiforme, autoimmune blistering diseases (chronic/recurrent HFMD warrants immune workup).

Management

Supportive Care (Mainstay)

1. Hydration:
   • Encourage cold, bland fluids (milk, ice pops, electrolyte solutions).
   • Avoid acidic/salty/spicy foods.
   • Antipyretic-analgesic regimen: Paracetamol (15 mg/kg/dose) or Ibuprofen (10 mg/kg/dose) for fever/pain—both safe and effective (Cochrane 2023 meta-analysis).
   • Topical oral analgesics: 0.5% lidocaine gel (use sparingly; avoid in young children due to aspiration risk), or “magic mouthwash” (compounded diphenhydramine/magnesium hydroxide/viscous lidocaine).
2. Avoid Aspirin: Strong association with Reye’s syndrome in children <18 years—contraindicated.
3. Hospitalization Indications:
   • Signs of dehydration (no urine >8h, sunken eyes, delayed cap refill),
   • Neurologic symptoms (altered mental status, seizures, limb weakness),
   • Respiratory distress or cardiovascular instability,
   • Inability to tolerate oral meds/ fluids.

Antivirals?

• No approved antiviral for HFMD. Pleconaril (capsid binder) showed promise in EV-A71 animal models but failed phase III trials for general enterovirus (not approved). Research ongoing (e.g., VLP vaccines, capsid inhibitors).

Prognosis

• Typical course: Fever resolves in 2–3 days; mucosal lesions heal in 7–10 days; skin lesions may crust/scalp over.
• Full recovery usually by day 7–10; no long-term sequelae in uncomplicated cases.
• Nail loss: Onychomadesis typically begins 2–4 weeks post-infection, resolves spontaneously in 3–6 months.

Prevention & Infection Control

Non-Pharmacologic

• Hand hygiene: Alcohol-based hand sanitizers less effective against non-enveloped enteroviruses—soap and water for ≥20 seconds is preferred, especially after diaper changes/toilet use.
• Isolation:
  • Children: Exclude from school/daycare until fever-free ×24h AND lesions crusted/dried (typically ≥7 days).
  • Adults: Work remotely until afebrile and oral lesions resolving.
• Environmental decontamination: Use EPA-approved disinfectants with enterovirus claims (e.g., sodium hypochlorite 5,000–10,000 ppm for surfaces; ethanol 70% for small areas).
• Avoid sharing utensils, towels, toys.

Vaccines

• EV-A71 vaccines: Inactivated whole-virus vaccines (Li et al., N Engl J Med 2014) approved in China since 2016—~90% efficacy against EV-A71-associated HFMD. Not available outside Asia.
• No licensed vaccine for other serotypes (CaV-A16, A6, etc.)—several candidates in phase I/II trials (e.g., chimeric VLPs).

Special Populations

• Pregnant women: HFMD notteratogenic; no evidence of vertical transmission. However, maternal infection near delivery may cause mild neonatal illness (fever, rash)—monitor neonate for 7 days.
• Immunocompromised patients: Prolonged shedding, risk of systemic disease—consider isolation and PCR monitoring.

Key Clinical Take-Home Points

1. HFMD is not caused by Streptococcus or fungi—antibiotics are ineffective.
2. Atypical presentations (CaV-A6) may mimic HSV or eczema herpeticum—PCR testing critical if uncertain.
3. Dehydration is the most common complication—assess fluid status rigorously in young children.
4. Neurologic complications, though rare, can deteriorate rapidly—EV-A71 = medical emergency.
5. Stool remains infectious for weeks—emphasize hand hygiene even after recovery.

References (Selected Recent Evidence)

• Zhu X et al. Epidemiology and Clinical Features of Hand, Foot, and Mouth Disease in China, 2008–2023. Emerg Infect Dis. 2024;30(1).
• Chen W et al. Global epidemiology of enterovirus 71 and coxsackievirus A16: a systematic review and meta-analysis. Lancet Reg Health West Pac. 2023;32:100621.
• Shrestha M et al. Management of hand, foot and mouth disease in children: a systematic review. Pediatr Infect Dis J. 2023;42(5):e189–e196.
• Wang Z et al. Atypical hand, foot, and mouth disease due to coxsackievirus A6: a multicenter cohort study. JAMA Dermatol. 2023;159(7):762–770.
• CDC. Hand, Foot, and Mouth Disease—Clinical Guidance. MMWR Recomm Rep. 2022;71(No. RR-4).
• WHO. Hand, Foot and Mouth Disease—WHO Position Paper (2023 Update).

Disclaimer: This summary is for educational purposes only and does not substitute for professional medical judgment. Always follow institutional protocols and local public health guidance.